{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T15:20:13Z","timestamp":1773242413728,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13300-022-01276-2","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T07:02:58Z","timestamp":1655276578000},"page":"35-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with  and Without T2D"],"prefix":"10.1007","volume":"13","author":[{"given":"Olga","family":"Gonz\u00e1lez-Albarr\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crist\u00f3bal","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"P\u00e9rez-Maraver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Juan","family":"Aparicio-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1276_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-med-042017-094221","volume":"70","author":"CK Kramer","year":"2019","unstructured":"Kramer CK, Zinman B. Sodium\u2013glucose cotransporter-2 (SGLT-2) inhibitors and the treatment of type\u00a02 diabetes. Annu Rev Med. 2019;70:323\u201334.","journal-title":"Annu Rev Med"},{"key":"1276_CR3","doi-asserted-by":"crossref","unstructured":"van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type\u00a02 diabetes management. Diabetes Care. 2018;41:1543\u201356.","DOI":"10.2337\/dc18-0588"},{"key":"1276_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1276_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1276_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1276_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1276_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1276_CR9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","volume":"94","author":"Y Xie","year":"2018","unstructured":"Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94:567\u201381.","journal-title":"Kidney Int"},{"key":"1276_CR10","first-page":"A6","volume":"2020","author":"R Saran","year":"2019","unstructured":"Saran R, Robinson B, Abbott KC, et al. Annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;2020:A6-7.","journal-title":"Am J Kidney Dis"},{"key":"1276_CR11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1276_CR12","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1001\/archinte.168.22.2440","volume":"168","author":"LD Bash","year":"2008","unstructured":"Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med. 2008;168:2440\u20137.","journal-title":"Arch Intern Med"},{"key":"1276_CR13","doi-asserted-by":"publisher","first-page":"14705","DOI":"10.1038\/s41598-021-94099-3","volume":"11","author":"O Buyadaa","year":"2021","unstructured":"Buyadaa O, Salim A, Morton JI, Magliano DJ, Shaw JE. Rate of decline in kidney function and known age-of-onset or duration of type\u00a02 diabetes. Sci Rep. 2021;11:14705.","journal-title":"Sci Rep"},{"key":"1276_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2215\/CJN.07650711","volume":"7","author":"G Zoppini","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type\u00a02 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7:401\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1276_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/dom.13550","volume":"21","author":"I Pearce","year":"2019","unstructured":"Pearce I, Sim\u00f3 R, L\u00f6vestam-Adrian M, Wong DT, Evans M. Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. Diabetes Obes Metab. 2019;21:467\u201378.","journal-title":"Diabetes Obes Metab"},{"key":"1276_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"1276_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2337\/dc11-1109","volume":"35","author":"R-D Ting","year":"2012","unstructured":"Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type\u00a02 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012;35:218\u201325.","journal-title":"Diabetes Care"},{"key":"1276_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13300-020-00952-5","volume":"12","author":"Q Li","year":"2021","unstructured":"Li Q, Wen F, Wang Y, et al. Diabetic kidney disease benefits from intensive low-protein diet: updated systematic review and meta-analysis. Diabetes Ther. 2021;12:21\u201336.","journal-title":"Diabetes Ther"},{"key":"1276_CR19","first-page":"S1","volume":"2020","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;2020:S1\u2013115.","journal-title":"Kidney Int"},{"key":"1276_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"key":"1276_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type\u00a02 diabetes. J Am Soc Nephrol. 2013;24:302\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1276_CR22","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/j.amjmed.2019.10.042","volume":"133","author":"MV Fangel","year":"2020","unstructured":"Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type\u00a02 diabetes without cardiovascular disease: a Danish cohort study. Am J Med. 2020;133:e269\u201379.","journal-title":"Am J Med"},{"key":"1276_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000496276","volume":"49","author":"U Anyanwagu","year":"2019","unstructured":"Anyanwagu U, Donnelly R, Idris I. Albuminuria regression and all-cause mortality among insulin-treated patients with type\u00a02 diabetes: analysis of a large UK primary care cohort. Am J Nephrol. 2019;49:146\u201355.","journal-title":"Am J Nephrol"},{"key":"1276_CR24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40620-020-00845-7","volume":"34","author":"A De Pascalis","year":"2021","unstructured":"De Pascalis A, Cianciolo G, Capelli I, Brunori G, La Manna G. SGLT2 inhibitors, sodium and off-target effects: an overview. J Nephrol. 2021;34:673\u201380.","journal-title":"J Nephrol"},{"key":"1276_CR25","doi-asserted-by":"crossref","unstructured":"Baker WL, Buckley LF, Kelly MS, et al. Effects of sodium\u2013glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6(5):e005686.","DOI":"10.1161\/JAHA.117.005686"},{"key":"1276_CR26","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317.","journal-title":"Diabetologia"},{"key":"1276_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium\u2013glucose cotransporter-2 inhibitors. Kidney Int. 2018;94:26\u201339.","journal-title":"Kidney Int"},{"key":"1276_CR28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type\u00a02 diabetes: an analysis from the DECLARE-TIMI\u00a058 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR29","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2337\/dc21-0076","volume":"44","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Wiviott SD, Heerspink HJL, et al. The effect of dapagliflozin on albuminuria in DECLARE-TIMI\u00a058. Diabetes Care. 2021;44:1805\u201315.","journal-title":"Diabetes Care"},{"key":"1276_CR30","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016;39:1108\u201314.","journal-title":"Diabetes Care"},{"key":"1276_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D, et al. Effects of sodium\u2013glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"1276_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Perco P, Mulder S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62:1154\u201366.","journal-title":"Diabetologia"},{"key":"1276_CR33","doi-asserted-by":"crossref","unstructured":"Pirklbauer M, Sallaberger S, Staudinger P, et al. Empagliflozin inhibits IL-1\u03b2-mediated inflammatory response in human proximal tubular cells. Int J Mol Sci. 2021;22(10):5089.","DOI":"10.3390\/ijms22105089"},{"key":"1276_CR34","doi-asserted-by":"crossref","unstructured":"Xu J, Kitada M, Ogura Y, Liu H, Koya D. Dapagliflozin restores impaired autophagy and suppresses inflammation in high glucose-treated HK-2 cells. Cells. 2021;10(6):1457.","DOI":"10.3390\/cells10061457"},{"key":"1276_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","volume":"98","author":"AC Hesp","year":"2020","unstructured":"Hesp AC, Schaub JA, Prasad PV, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int. 2020;98:579\u201389.","journal-title":"Kidney Int"},{"key":"1276_CR36","doi-asserted-by":"crossref","unstructured":"Bakris G, Oshima M, Mahaffey KW, et al. Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol. 2020;15:1705\u201314.","DOI":"10.2215\/CJN.10140620"},{"key":"1276_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR38","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.2337\/dc21-0300","volume":"44","author":"F Persson","year":"2021","unstructured":"Persson F, Rossing P, Vart P, et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care. 2021;44:1894\u20137.","journal-title":"Diabetes Care"},{"key":"1276_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type\u00a02 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:755\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR40","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HL Heerspink","year":"2021","unstructured":"Heerspink HL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type\u00a02 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.kint.2021.09.005","volume":"101","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Cherney D, Postmus D, et al. A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int. 2022;101:174\u201384.","journal-title":"Kidney Int"},{"key":"1276_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-8587(21)00295-3","volume":"10","author":"P Rossing","year":"2022","unstructured":"Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type\u00a02 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022;10:24\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","volume":"7","author":"C Pollock","year":"2019","unstructured":"Pollock C, Stef\u00e1nsson B, Reyner D, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type\u00a02 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac. Lancet Diabetes Endocrinol. 2019;7:429\u201341.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/dc14-2806","volume":"38","author":"AT Sands","year":"2015","unstructured":"Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181\u20138.","journal-title":"Diabetes Care"},{"key":"1276_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129\u201339.","journal-title":"N Engl J Med"},{"key":"1276_CR46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type\u00a02 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type\u00a02 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148\u201358.","journal-title":"JAMA Cardiol"},{"key":"1276_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025121","volume":"100","author":"M Qiu","year":"2021","unstructured":"Qiu M, Ding L, Zhou H. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type\u00a02 diabetes: a meta-analysis with trial sequential analysis. Medicine. 2021;100: e25121.","journal-title":"Medicine"},{"key":"1276_CR49","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Vizca\u00edno V, D\u00edez-Fern\u00e1ndez A, \u00c1lvarez-Bueno C, Mart\u00ednez-Alfonso J, Cavero-Redondo I. Safety and efficacy of SGLT2 inhibitors: a multiple-treatment meta-analysis of clinical decision indicators. J Clin Med. 2021;10(12):2713.","DOI":"10.3390\/jcm10122713"},{"key":"1276_CR50","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type\u00a02 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:1237\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"1276_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8:27\u201335.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR52","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.2337\/dc22-S011","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes\u20142022. Diabetes Care. 2022;45:S175\u201384.","journal-title":"Diabetes Care"},{"key":"1276_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J Engl. 2020;41:255\u2013323.","journal-title":"Eur Heart J Engl"},{"key":"1276_CR54","doi-asserted-by":"crossref","unstructured":"de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020:98:839\u201348.","DOI":"10.1016\/j.kint.2020.06.024"},{"key":"1276_CR55","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"J Rangaswami","year":"2020","unstructured":"Rangaswami J, Bhalla V, de Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020;142:e265\u201386.","journal-title":"Circulation"},{"key":"1276_CR56","doi-asserted-by":"publisher","unstructured":"Fontes-Carvalho R, Santos-Ferreira D, Raz I, Marx N, Ruschitzka F, Cosentino F. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. Eur J Prev Cardiol. 2021; zwab034. https:\/\/doi.org\/10.1093\/eurjpc\/zwab034","DOI":"10.1093\/eurjpc\/zwab034"},{"key":"1276_CR57","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1276_CR58","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1276_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121\u20138.","journal-title":"Lancet"},{"key":"1276_CR60","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","volume":"22","author":"KI Birkeland","year":"2020","unstructured":"Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type\u00a02 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22:1607\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"1276_CR61","doi-asserted-by":"crossref","unstructured":"Ronco C, Ronco F, McCullough PA. A call to action to develop integrated curricula in cardiorenal medicine. Blood Purif. 2017;44:251\u20139.","DOI":"10.1159\/000480318"},{"key":"1276_CR62","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s13300-018-0470-9","volume":"9","author":"E Han","year":"2018","unstructured":"Han E, Kim A, Lee SJ, et al. Characteristics of dapagliflozin responders: a longitudinal, prospective, nationwide dapagliflozin surveillance study in Korea. Diabetes Ther. 2018;9:1689\u2013701.","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01276-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-022-01276-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01276-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T07:01:34Z","timestamp":1656486094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-022-01276-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":62,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s13300-022-01276-2","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}